Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rizzieri

Showing results (71-80 of 132) with videos related to

Pageof 14
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 2, 2010
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantationDavid A Rizzieri, Robert Storms, Dong-Feng Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2003
4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemiaDavid A Rizzieri, Jeffrey T Talbot, Gwynn D Long, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 16, 2012
Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantationJunya Kanda, Lun-Wei Chiou, Paul Szabolcs, et al.
Blood Cancer Journal|May 17, 2021
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplantCindy M Pabon, Zhiguo Li, Therese Hennig, et al.
Blood|April 22, 2004
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaDavid A Rizzieri, Gamal Akabani, Michael R Zalutsky, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
The New England Journal of Medicine|April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmNaveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Bone Marrow Transplantation|July 7, 2020
Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantationKo K Maung, Benny J Chen, Ian Barak, et al.
Cell Metabolism|February 19, 2019
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug SensitivityKevin H Lin, Abigail Xie, Justine C Rutter, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Pageof 14

Showing results (71-80 of 132) with videos related to

Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 2, 2010
Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantationDavid A Rizzieri, Robert Storms, Dong-Feng Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2003
4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemiaDavid A Rizzieri, Jeffrey T Talbot, Gwynn D Long, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 16, 2012
Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantationJunya Kanda, Lun-Wei Chiou, Paul Szabolcs, et al.
Blood Cancer Journal|May 17, 2021
Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplantCindy M Pabon, Zhiguo Li, Therese Hennig, et al.
Blood|April 22, 2004
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaDavid A Rizzieri, Gamal Akabani, Michael R Zalutsky, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
The New England Journal of Medicine|April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell NeoplasmNaveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Bone Marrow Transplantation|July 7, 2020
Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantationKo K Maung, Benny J Chen, Ian Barak, et al.
Cell Metabolism|February 19, 2019
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug SensitivityKevin H Lin, Abigail Xie, Justine C Rutter, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Pageof 14